BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol 2021;6:eabf4034. [PMID: 34739340 DOI: 10.1126/sciimmunol.abf4034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Copic D, Direder M, Klas K, Bormann D, Laggner M, Ankersmit HJ, Mildner M. Antithymocyte Globulin Inhibits CD8+ T Cell Effector Functions via the Paracrine Induction of PDL-1 on Monocytes. Cells 2023;12:382. [DOI: 10.3390/cells12030382] [Reference Citation Analysis]
2 Gutiérrez-Melo N, Baumjohann D. T follicular helper cells in cancer. Trends Cancer 2023:S2405-8033(22)00270-9. [PMID: 36642575 DOI: 10.1016/j.trecan.2022.12.007] [Reference Citation Analysis]
3 Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of checkpoint blockade-associated toxicity. J Exp Med 2023;220. [PMID: 36622383 DOI: 10.1084/jem.20220948] [Reference Citation Analysis]
4 Lee JM, Sage PT. Check(point) yourself before you wreck yourself in tumors. Nat Immunol 2023;24:10-1. [PMID: 36596895 DOI: 10.1038/s41590-022-01391-z] [Reference Citation Analysis]
5 Copic D, Direder M, Klas K, Bormann D, Laggner M, Ankersmit HJ, Mildner M. Antithymocyte globulin inhibits CD8+ T cell effector functions via the paracrine induction of PDL-1 on monocytes.. [DOI: 10.1101/2022.07.26.501584] [Reference Citation Analysis]
6 Cowles SC, Sheen A, Santollani L, Lutz EA, Lax BM, Palmeri JR, Freeman GJ, Wittrup KD. An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy. MAbs 2022;14:2088454. [PMID: 35924382 DOI: 10.1080/19420862.2022.2088454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]